Physicians' Academy for Cardiovascular Education

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Treatment of patients on oral anticoagulation who present with ACS

Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Promise of epigenetic modulation as a target in atherosclerotic patients

Aug. 26, 2017 - Barcelona, Spain - Erik SG Stroes, MD, Amsterdam, the Netherlands - PACE-CME symposium at ESC 2017

Management of CV Risk & T2DM: Implications of novel outcome trials

Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

Take home messages of the ESC congress for better hypertension treatment

Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

MRA treatment early after STEMI may give mortality benefit

Aug. 30, 2017

A new challenge for precision medicine: selecting major contributing risk factors

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

The Clinical Unmet need in the patient with Diabetes and ACS

Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

Aug. 29, 2017 - ESC 2017, Barcelona, Spain

SGLT2 inhibition in cardiology: What a cardiologist needs to know

Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017
Lecture by Prof Stephen Nicholls held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

Hyper- and hypokalaemia associated with increased mortality in chronic heart failure

Oct. 19, 2017 - Aldahl M, et al. - European Heart Journal 2017

In chronic HF patients, the short-term all-cause mortality was increased in those with hypo- and hyperkalaemia, as well as in those in the lower and upper levels of the normal potassium range.

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Midlife hypertension is associated with an increased risk of dementia in women

Oct. 19, 2017 - Gilsanz P, et al. - Neurology 2017

Although midlife hypertension is more common in men, it was only associated with the risk of dementia in women, suggesting that hypertension is a modifiable risk factor for dementia in women.

NT-proBNP levels predict outcomes in HF patients with or without atrial fibrillation

Oct. 19, 2017 - Kristensen SL et al. - Circ Heart Fail. 2017

a concentration of 400 pg/mL, any given concentration of NT-proBNP had a similar predictive value for adverse outcomes in HFrEF patients with and without AF.

BET inhibition may lower CV events in high risk CVD patients, suggests hypothesis-generating analysis

Oct. 18, 2017 - Nicholls SJ et al. - Am J Cardiovasc Drugs. 2017

Pooled analysis of phase II studies evaluating apabetalone suggest that this epigenetic therapeutic may yield clinical benefit for CVD patients with low HDL-C, diabetes, and elevated hsCRP levels.

SBP variability is associated with clinical outcomes in atrial fibrillation patients

Oct. 17, 2017 - Proietti M, et al. - Hypertension 2017

In the AFFIRM study, SBP variability was inversely associated with the quality of anticoagulation control in AF patients, and increasing SBP variability was associated with a higher risk of major adverse clinical outcomes.

NAVIGATE ESUS study stopped early due to comparable efficacy between treatment arms

Oct. 17, 2017 - news

The phase III study evaluated rivaroxaban vs aspirin in patients with embolic stroke of undetermined source. An interim analysis indicated no benefit of the NOAC over aspirin in reducing recurrent events.

ESC/EAS Task Force published update of clinical guidance for use of PCSK9 inhibitors

Oct. 17, 2017 - news

The practical clinical guidance aims to help clinicals identify very high risk patients with substantially elevated LDL-c despite treatment, who are likely to benefit most from treatment with PCSK9 inhibition

Potent P2Y12 receptor inhibitor shows stronger antithrombotic effect in T2DM patients with CVD

Oct. 17, 2017 - Zafar MU, et al. - Thromb Haemost 2017

A randomized, cross-over study showed a stronger antiplatelet effect and a faster and more potent antithrombotic effect with ticagrelor than with clopidogrel in T2DM patients with stable CVD.

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK
Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Lipid parameters strongly depend on age and sex

Oct. 16, 2017 - Balder JW et al., - J Clin Lipidol. 2017

Based on data of the large Dutch Lifelines cohort, reference values have been developed for lipid parameters.